The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1587
ISSUE 1587
December 16, 2019
Issue 1587
| Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Trifarotene (Aklief) - A New Topical Retinoid for Acne
December 16, 2019 (Issue: 1587)
The FDA has approved trifarotene 0.005% cream
(Aklief – Galderma) for topical treatment of acne
vulgaris in patients ≥9 years old. Trifarotene is the
fourth topical retinoid to be approved in the US for
treatment of acne; tretinoin (Retin-A, and others),
adapalene (Differin, and generics), and tazarotene
(Tazorac, and others) have been available by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment of
acne in patients ≥12 years old.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1587
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
